SMMT
Income statement / Annual
Last year (2024), Summit Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Summit Therapeutics Inc.'s net income was -$221.32 M.
See Summit Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
01/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$704.30 K |
$1.81 M |
$860.00 K |
$611.87 K |
$56.41 M |
$17.50 M |
$2.88 M |
$1.28 M |
| Cost of Revenue |
$15.01 M
|
$2.05 M
|
$2.51 M
|
$0.00
|
$0.00
|
$155.40 K
|
$24.92 K
|
$97.67 K
|
$0.00
|
$0.00
|
| Gross Profit |
-$15.01 M
|
-$2.05 M
|
-$1.81 M
|
$1.81 M
|
$860.00 K
|
$476.62 K
|
$56.39 M
|
$17.40 M
|
$2.88 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
-2.57
|
1
|
1
|
0.78
|
1
|
0.99
|
1
|
0
|
| Research and Development Expenses |
$150.78 M
|
$59.47 M
|
$52.00 M
|
$85.35 M
|
$53.27 M
|
$39.18 M
|
$51.38 M
|
$41.01 M
|
$23.69 M
|
$23.94 M
|
| General & Administrative Expenses |
$60.53 M
|
$23.74 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$9.29 M
|
$16.19 M
|
$16.98 M
|
$9.62 M
|
$7.45 M
|
| Selling & Marketing Expenses |
$0.00
|
-$2.05 M
|
$0.00
|
$0.00
|
$0.00
|
$2.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$48.35 M
|
$30.27 M
|
$26.70 M
|
$23.61 M
|
$19.23 M
|
$9.30 M
|
$17.01 M
|
$13.71 M
|
$9.62 M
|
$7.45 M
|
| Other Expenses |
-$250.00 K
|
$0.00
|
-$5.95 M
|
-$20.97 M
|
-$13.49 M
|
-$18.84 M
|
-$14.41 M
|
-$743.00 K
|
$639.98 K
|
-$3.14 M
|
| Operating Expenses |
$211.30 M
|
$87.69 M
|
$64.28 M
|
$88.00 M
|
$53.19 M
|
$39.18 M
|
$47.69 M
|
$54.13 M
|
$33.95 M
|
$29.45 M
|
| Cost And Expenses |
$226.31 M
|
$89.74 M
|
$72.79 M
|
$65.07 M
|
$54.05 M
|
$43.40 M
|
$51.70 M
|
$54.13 M
|
$33.95 M
|
$29.45 M
|
| Interest Income |
$0.00
|
$10.40 M
|
$1.51 M
|
$178.95 K
|
$4.00 K
|
$4.34 K
|
$5.00 K
|
$4.38 M
|
$10.00 K
|
$30.00 K
|
| Interest Expense |
$0.00
|
$16.46 M
|
$4.40 M
|
$281.00 K
|
$255.00 K
|
$32.52 K
|
$620.00 K
|
$1.65 M
|
$1.08 M
|
$0.00
|
| Depreciation & Amortization |
$17.15 M
|
$155.32 K
|
$1.26 M
|
$2.46 M
|
$2.00 M
|
$1.39 M
|
$1.95 M
|
$348.21 K
|
$72.50 K
|
$68.36 K
|
| EBITDA |
-$212.85 M |
$1.00 M |
-$73.12 M |
-$85.91 M |
-$50.65 M |
-$16.80 M |
$11.66 M |
-$32.19 M |
-$30.98 M |
-$20.30 M |
| EBITDA Ratio |
0
|
0
|
-103.82
|
-47.49
|
-58.9
|
-27.45
|
0.21
|
-1.84
|
-10.76
|
-15.85
|
| Operating Income Ratio |
0
|
0
|
-84.67
|
-47.64
|
-61.85
|
-36.98
|
0.1
|
-2.09
|
-10.79
|
-22.43
|
| Total Other Income/Expenses Net |
-$221.63 M
|
-$526.14 M
|
-$6.69 M
|
-$2.42 M
|
$206.94 K
|
-$10.16 M
|
$3.69 M
|
$1.91 M
|
-$1.07 M
|
-$2.85 M
|
| Income Before Tax |
-$221.32 M
|
-$615.87 M
|
-$78.78 M
|
-$88.60 M
|
-$52.91 M
|
-$28.41 M
|
$9.08 M
|
-$33.86 M
|
-$32.13 M
|
-$23.20 M
|
| Income Before Tax Ratio |
0
|
0
|
-111.86
|
-48.98
|
-61.52
|
-46.43
|
0.16
|
-1.94
|
-11.16
|
-18.11
|
| Income Tax Expense |
$0.00
|
-$946.00 K
|
-$4.40 M
|
-$2.46 M
|
-$213.00 K
|
-$4.52 M
|
-$1.79 M
|
-$5.33 M
|
-$5.42 M
|
-$4.36 M
|
| Net Income |
-$221.32 M
|
-$614.93 M
|
-$78.78 M
|
-$88.60 M
|
-$52.70 M
|
-$23.88 M
|
$9.87 M
|
-$28.53 M
|
-$21.37 M
|
-$24.34 M
|
| Net Income Ratio |
0
|
0
|
-111.86
|
-48.98
|
-61.28
|
-39.04
|
0.17
|
-1.63
|
-7.42
|
-19
|
| EPS |
-0.31 |
-0.99 |
-0.41 |
-0.96 |
-0.76 |
-0.15 |
0.11 |
-0.16 |
-0.43 |
-0.41 |
| EPS Diluted |
-0.31 |
-0.99 |
-0.38 |
-0.96 |
-0.76 |
-0.15 |
0.11 |
-0.15 |
-0.43 |
-0.41 |
| Weighted Average Shares Out |
$718.54 M
|
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$32.73 M
|
$86.14 M
|
$65.03 M
|
$61.55 M
|
$59.10 M
|
| Weighted Average Shares Out Diluted |
$718.54 M
|
$619.65 M
|
$193.34 M
|
$92.24 M
|
$69.52 M
|
$32.83 M
|
$86.14 M
|
$65.43 M
|
$61.55 M
|
$59.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
